Sorafenib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Unspecified Adult Solid Tumor, Protocol Specific

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Trial Timeline

Dec 1, 2008 → Mar 1, 2012

NCT ID

NCT00810394

About Sorafenib

Sorafenib is a phase 2 stage product being developed by Bayer for Unspecified Adult Solid Tumor, Protocol Specific. The current trial status is completed. This product is registered under clinical trial identifier NCT00810394. Target conditions include Unspecified Adult Solid Tumor, Protocol Specific.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02311205	Phase 2	UNKNOWN	Dec 1, 2014	Jun 1, 2018	Hepatocellular Carcinoma
NCT01724606	Phase 1	Completed	Nov 5, 2012	Mar 1, 2022	Breast Cancer
NCT01510756	Phase 2	Terminated	Dec 1, 2011	Dec 1, 2014	Chronic Lymphocytic Leukemia
NCT01159327	Phase 2	Terminated	Dec 1, 2010	Jun 1, 2013	Small Cell Lung Cancer
NCT01005875	Pre-clinical	Terminated	Nov 1, 2009	Jun 1, 2013	Hepatocellular Carcinoma
NCT00954278	Phase 1	Completed	Jul 28, 2009	Dec 23, 2015	Carcinoma, Non Small Cell Lung
NCT00813293	Phase 2	Completed	Jun 1, 2009	Nov 1, 2013	Hepatocellular Cancer
NCT00864032	Phase 1/2	Completed	Mar 1, 2009	Aug 1, 2011	Soft Tissue Sarcoma
NCT00844883	Phase 2	Completed	Feb 1, 2009	Mar 1, 2015	Hepatocellular Carcinoma
NCT00810394	Phase 2	Completed	Dec 1, 2008	Mar 1, 2012	Unspecified Adult Solid Tumor, Protocol Specific
NCT00794859	Phase 2	UNKNOWN	Oct 1, 2008	—	Mesothelioma
NCT00754923	Phase 2	Terminated	Oct 1, 2008	Apr 1, 2012	Lung Cancer
NCT00712790	Phase 1/2	Completed	Jun 1, 2008	Apr 1, 2014	Hepatocellular Carcinoma
NCT01189370	Phase 2	Completed	Jun 1, 2008	Apr 1, 2015	Renal Cell Cancer
NCT00543335	Phase 1	Terminated	Jan 25, 2008	Jan 1, 2011	Lung Cancer
NCT00572078	Phase 1	Completed	Jan 23, 2008	Sep 14, 2014	SOLID TUMORS
NCT00525161	Phase 2	Terminated	Oct 1, 2007	Jan 1, 2015	Breast Cancer
NCT00480389	Phase 2	Completed	May 1, 2007	Mar 1, 2013	Renal Cell Carcinoma
NCT00478114	Phase 3	Completed	May 1, 2007	Mar 1, 2010	Renal Cell Carcinoma
NCT00496756	Phase 2	Terminated	Mar 1, 2007	Apr 25, 2014	Kidney Cancer

Competing Products

20 competing products in Unspecified Adult Solid Tumor, Protocol Specific

See all competitors

Product	Company	Stage	Hype Score
DJ-927 + capecitabine	Daiichi Sankyo	Phase 1	33
E7389 + E7389 + E7389	Eisai	Phase 1	33
bevacizumab + enzastaurin hydrochloride	Eli Lilly	Phase 1	33
SHR-1916	Jiangsu Hengrui Medicine	Phase 1	33
Pembrolizumab	Merck	Phase 2	52
PI3K inhibitor BKM120 + docetaxel	Novartis	Phase 1	33
bevacizumab + cyclophosphamide + imatinib	Novartis	Phase 1	33
capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)	Novartis	Phase 1	33
warfarin	Novartis	Phase 1	33
RLY-1971	Roche	Phase 1	33
Domvanalimab + Zimberelimab	Gilead Sciences	Phase 1	32
BEZ235 + MEK162	Pfizer	Phase 1	32
Utomilumab + ISA101b	Pfizer	Phase 2	51
Irinotecan	Pfizer	Phase 1	32
Ixabepilone + Sunitinib	Pfizer	Phase 1	32
ixabepilone + lapatinib ditosylate	Bristol Myers Squibb	Phase 1	32
carboplatin + irinotecan hydrochloride	Bristol Myers Squibb	Phase 1	32
intoplicine	Sanofi	Phase 1	32
apomine	Sanofi	Phase 1	32
apomine	Sanofi	Phase 1	32

Other Products from Bayer

TelmisartanApproved

Clotrimazole vaginal tablet + FluconazoleApproved

Levitra (Vardenafil, BAY38-9456)Approved

Avelox (Moxifloxacin, BAY12-8039) + Amoxicillin clavulanic acidApproved

Rivaroxaban 20 MG + WarfarinApproved